Regulon: R-203
Regulons
are regulatory units consisting of a coherently expressed set of genes and the associated regulator(s) whose binding site(s) they share.
Regulon Summary
Regulon summary table displays all associated information related to the specific regulon including the number of genes in the regulon, Hazard ratio
, its Regulator
, the Transcriptional Program
that includes the regulon, Drugs that are associated with members of the regulon, together with mechanism of action and class, and enriched hallmarks of cancer if any.
Genes | Cox Hazard Ratio | Regulators | Causal Flows | Transcriptional Programs | Hallmarks |
---|---|---|---|---|---|
38 | 2.05918 | 1 | 9 | Pr-7 | ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
Regulon Genes
List of genes that are included in the regulon. These genes have similar expression profiles in subset of patients and they share common binding motif for the Regulator
of the regulon. Clicking on the gene name will take you to the gene specific page with more details. Please wait while information is collated from several resources after you click.
Regulon Drugs
Name | Approved Symbol | Type | Action Type | Mechanism of Action | Max Trial Phase | Max GBM Phase |
---|---|---|---|---|---|---|
FOSTAMATINIB DISODIUM | SYK | Small molecule | INHIBITOR | Tyrosine-protein kinase SYK inhibitor | 4 | 0 |
INFLIXIMAB | TNF | Antibody | INHIBITOR | TNF-alpha inhibitor | 4 | 0 |
MIDOSTAURIN | KIT | Small molecule | INHIBITOR | Vascular endothelial growth factor receptor 2 inhibitor | 4 | 0 |
ATN-161 | ITGB3 | Protein | ANTAGONIST | Integrin alpha-5/beta-1 antagonist | 2 | 0 |
CSL-324 | CSF3R | Unknown | ANTAGONIST | Granulocyte colony stimulating factor receptor antagonist | 2 | 0 |
ONERCEPT | TNF | Protein | INHIBITOR | TNF-alpha inhibitor | 3 | 0 |
R-343 | SYK | Small molecule | INHIBITOR | Tyrosine-protein kinase SYK inhibitor | 2 | 0 |
BIIB-023 | TNFSF12 | Antibody | INHIBITOR | Tumor necrosis factor ligand superfamily member 12 inhibitor | 2 | 0 |
DASATINIB | ABL1 | Small molecule | INHIBITOR | Platelet-derived growth factor receptor beta inhibitor | 4 | 2 |
R-348 | SYK | Small molecule | INHIBITOR | Tyrosine-protein kinase SYK inhibitor | 2 | 0 |
AMY-101 | C3 | Protein | INHIBITOR | Complement C3 inhibitor | 2 | 0 |
LIPEGFILGRASTIM | CSF3R | Protein | AGONIST | Granulocyte colony stimulating factor receptor agonist | 4 | 0 |
PEGSUNERCEPT | TNF | Protein | INHIBITOR | TNF-alpha inhibitor | 2 | 0 |
GOLIMUMAB | TNF | Antibody | INHIBITOR | TNF-alpha inhibitor | 4 | 0 |
CERDULATINIB | JAK1 | Small molecule | INHIBITOR | Tyrosine-protein kinase JAK1 inhibitor | 2 | 0 |
FILGRASTIM | CSF3R | Protein | AGONIST | Granulocyte colony stimulating factor receptor agonist | 4 | 0 |
HMPL-523 | SYK | Small molecule | INHIBITOR | Tyrosine-protein kinase SYK inhibitor | 1 | 0 |
ETANERCEPT | TNF | Protein | INHIBITOR | TNF-alpha inhibitor | 4 | 0 |
BALUGRASTIM | CSF3R | Protein | AGONIST | Granulocyte colony stimulating factor receptor agonist | 2 | 0 |
AFELIMOMAB | TNF | Antibody | INHIBITOR | TNF-alpha inhibitor | 0 | 0 |
SOTRASTAURIN | PRKD3 | Small molecule | INHIBITOR | Protein kinase C (PKC) inhibitor | 2 | 0 |
OZORALIZUMAB | TNF | Antibody | INHIBITOR | TNF-alpha inhibitor | 2 | 0 |
ILORASERTIB | PDGFRB | Small molecule | INHIBITOR | Serine/threonine-protein kinase Aurora inhibitor | 2 | 0 |
CERTOLIZUMAB PEGOL | TNF | Antibody | INHIBITOR | TNF-alpha inhibitor | 4 | 0 |
RO-5458640 | TNFSF12 | Antibody | INHIBITOR | Tumor necrosis factor ligand superfamily member 12 inhibitor | 1 | 0 |
UCN-01 | CDK4 | Small molecule | INHIBITOR | 3-phosphoinositide dependent protein kinase-1 inhibitor | 2 | 0 |
PF-04605412 | ITGA5 | Antibody | INHIBITOR | Fibronectin receptor alpha inhibitor | 1 | 0 |
NEIHULIZUMAB | SELPLG | Antibody | INHIBITOR | P-selectin glycoprotein ligand 1 inhibitor | 2 | 0 |
XL-228 | ABL1 | Small molecule | INHIBITOR | Tyrosine-protein kinase ABL inhibitor | 1 | 0 |
ENTOSPLETINIB | SYK | Small molecule | INHIBITOR | Tyrosine-protein kinase SYK inhibitor | 2 | 0 |
R-333 | SYK | Small molecule | INHIBITOR | Tyrosine-protein kinase SYK inhibitor | 2 | 0 |
GUSACITINIB | SYK | Small molecule | INHIBITOR | Janus Kinase (JAK) inhibitor | 2 | 0 |
REMTOLUMAB | TNF | Antibody | INHIBITOR | Interleukin 17A inhibitor | 2 | 0 |
TG100-801 | EPHB4 | Small molecule | INHIBITOR | SRC inhibitor | 2 | 0 |
PEGCETACOPLAN | C3 | Protein | INHIBITOR | Complement C3 inhibitor | 4 | 0 |
LENOGRASTIM | CSF3R | Protein | AGONIST | Granulocyte colony stimulating factor receptor agonist | 4 | 0 |
MIVAVOTINIB CITRATE | SYK | Small molecule | INHIBITOR | Tyrosine-protein kinase SYK inhibitor | 2 | 0 |
ADALIMUMAB | TNF | Antibody | INHIBITOR | TNF-alpha inhibitor | 4 | 0 |
VOLOCIXIMAB | ITGB1 | Antibody | ANTAGONIST | Integrin alpha-5/beta-1 antagonist | 3 | 0 |
FOSTAMATINIB | SYK | Small molecule | INHIBITOR | Tyrosine-protein kinase SYK inhibitor | 4 | 0 |
PLACULUMAB | TNF | Antibody | INHIBITOR | TNF-alpha inhibitor | 2 | 0 |
DELCASERTIB | PRKCD | Protein | INHIBITOR | Protein kinase C delta inhibitor | 2 | 0 |
LANRAPLENIB | SYK | Small molecule | INHIBITOR | Tyrosine-protein kinase SYK inhibitor | 2 | 0 |
MIVAVOTINIB | SYK | Small molecule | INHIBITOR | Tyrosine-protein kinase SYK inhibitor | 2 | 0 |
PEGFILGRASTIM | CSF3R | Protein | AGONIST | Granulocyte colony stimulating factor receptor agonist | 4 | 0 |
VESENCUMAB | NRP1 | Antibody | INHIBITOR | Neuropilin-1 inhibitor | 1 | 0 |
GSK-690693 | PRKACB | Small molecule | INHIBITOR | Protein kinase C (PKC) inhibitor | 1 | 0 |
AL-78898A | C3 | Unknown | INHIBITOR | Complement C3 inhibitor | 2 | 0 |
ENMD-981693 | PDGFRB | Small molecule | INHIBITOR | Platelet-derived growth factor receptor inhibitor | 2 | 0 |
Causal Flows
Causal Flows
are statistically significant links between putative causal events (somatic mutations, copy number variations, chromosomal translocations, etc.) and the activity levels of regulators and regulons. In the causal flow a mutation
may causally activates or deactivates a downstream regulator
which then might up- or down-regulates a regulon
that contains genes with similar expression profiles and binding sites.